[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gynaecological-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gynaecological-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100582421","in-vivo-dosimetry-for-brachytherapy-study-100582421",false,"NCT06863090","In Vivo Dosimetry for Brachytherapy Study","A Single-centre Feasibility Study Investigating the Use of in Vivo Dosimetry in Patients Receiving High Dose Rate (HDR) Brachytherapy for Gynaecological and Prostate Cancers","Inclusion Criteria:\n\n* Patients aged 18 years and above\n* Patients receiving HDR brachytherapy using iridium-192 (192Ir) radioactive source either as a monotherapy or in combination with external beam radiotherapy for:\n\n  1. histologically\u002Fradiologically proven primary or locally recurrent prostate cancer\n  2. locally advanced gynaecological malignancy in the primary and recurrent setting\n\n     * primary cervix carcinoma (squamous, adenocarcinoma, adenosquamous) FIGO IB2-IVA\n     * primary vulval FIGO I-IVA\n     * primary vaginal FIGO I-IVA\n     * primary endometrial cancer FIGO Stage I-IVA (not suitable for surgery)\n     * endometrial cancer receiving adjuvant vaginal vault brachytherapy\n     * recurrent cervix, vulval, vaginal or endometrial cancer suitable for brachytherapy as discussed in a regional gynae-oncology multidisciplinary meeting.\n* World Health Organisation (WHO) or Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\nExclusion Criteria:\n\n* Previous brachytherapy exposure to the treatment site\n* Patients unable to give informed consent\n* Patients unable to have a regional or general anaesthetic\n* Patients with the following medical conditions: coagulopathies, history of another primary malignancy, known allergy or sensitivity to study materials; previous or current fistulae\n* Not able to understand the implications of participating in the study in English\n* Patients with recent (within the last 6 months) or currently participating in interventional research","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","OBSERVATIONAL","The main study aim is the investigate the clinical use of in vivo dosimeters (small measurement devices) for brachytherapy (internal radiotherapy).",[24,25],"Prostate Cancer","Gynaecological Cancer","RECRUITING","2025-03-07",{"date":29,"type":30},"2025-03-11","ACTUAL",{"date":32,"type":20},"2025-03-03",{"date":34,"type":20},"2026-03-01",{"name":36,"class":37},"East and North Hertfordshire NHS Trust","OTHER_GOV",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":38},"100450181","palliation-in-gynae-oncology-patients-expectations-and-assessment-of-care-peace-100450181","NCT05142150","Palliation in Gynae-oncology: Patients Expectations and Assessment of Care (PEACE)","Palliation in Gynae-oncology: Patients Expectations and Assessment of Care","PEACE","Inclusion Criteria:\n\nA patient will be eligible for inclusion only if all of the following criteria are fulfilled:\n\n1. Patients with any advanced gynecological malignancy and a life expectancy of approximately 4 months as estimated by their treating physician\\*. Potential patient groups include, but are not limited to, those with platinum-resistant\u002Frefractory recurrent epithelial ovarian cancer (PRR-EOC), metastatic\u002Frecurrent cervical or endometrial cancer progressing after platinum-based chemotherapy; high grade\u002Fundifferentiated metastatic uterine sarcoma progressing after first-line chemotherapy etc.\n2. Patients may be on active cancer treatment, about to commence active cancer treatment or under observation\u002Fpalliative care.\n3. Age ≥ 18 years\n4. Able (both physically and cognitively) to complete patient-reported outcome measures independently in languages that are available in this study (i.e. without assistance from hospital translator).\n\nExclusion Criteria:\n\nA patient will not be eligible for inclusion if any of the following criteria are fulfilled:\n\n1. Unable to be comply with the protocol.\n2. A medical or psychological condition that limits the patient´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.\n3. Participation in another clinical trial.\n\nA patient will be asked to appoint a carer.\n\nInclusion criteria carer:\n\n1. Age ≥ 18 years\n2. A relative or close friend who is actively supporting the patient in her illness\n3. Able (both physically and cognitively) to complete questionnaires independently in languages that are available in this study (i.e. without assistance from hospital translator).\n\nExclusion criteria carer\n\nA carer will not be eligible for inclusion if any of the following criteria are fulfilled:\n\n1. Unable to be comply with the protocol\n2. A medical or psychological condition that limits the carer´s capacity to give informed consent, such as cognitive impairment, delirium, psychosis etc.","FEMALE",{"count":49,"type":20},73,"6 Weeks","The overall aim is to assess the feasibility and acceptability of collecting data on the patients and carers perception of care as well as to prospectively monitor end of life care.",[25],"2024-09-27",{"date":55,"type":30},"2024-10-01",{"date":57,"type":30},"2023-01-12",{"date":59,"type":20},"2027-12-31",{"name":61,"class":62},"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","OTHER",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100509848","side-effects-screening-and-early-intervention-to-impact-in-quality-of-life-of-gynaecological-cancer-patients-100509848","NCT05918770","Side Effects Screening and Early Intervention to Impact in Quality of Life of Gynaecological Cancer Patients","Telemedicine-guided Patients Reported Outcome Measures (PROMs): Side Effects Screening and Early Intervention to Impact in Quality of Life of Gynaecological Cancer Patients","HALIS","Inclusion Criteria:\n\n* Women aged ≥18 diagnosed with ovarian, tubal and primary peritoneal, cervical and endometrial cancer who are candidates for surgery during the study period.\n\nExclusion Criteria:\n\n* Patients unable to complete by themselves the screening questionnaires included.",{"count":72,"type":20},168,"INTERVENTIONAL",[75],"NA","The goal of this randomized study is to assess the impact on self-perceived quality of life (QoL) of systematic screening and early treatment of aftereffects in patients with gynaecological cancers. The main question it aims to answer is if systematic screening with validated questionaries (see in detailed description), diagnosis and early treatment of lower-limb lymphoedema, anxiety-depression, sexual dysfunction and sarcopenia-malnutrition all have a positive impact on the self-perceived QoL by gynaecological cancer patients. Participants will access the screening questionnaires and QoL questionaries on a free online app on their mobile devices. In the experimental group, in case of positive screening, patients will be referred to specialised care to early treatment of the aftereffects. Researchers will compare this group with standard usual care (opportunistic treatment) to see if systematic screening and early treatment lead to a better QoL.",[78,25,79,80],"Quality of Life","Lymphedema, Lower Limb","Sexual Dysfunction",[82,83],"quality of life","Gynaecological cancer","NOT_YET_RECRUITING","2023-06-23",{"date":87,"type":30},"2023-06-26",{"date":89,"type":20},"2023-09",{"date":91,"type":20},"2026-09",{"name":93,"class":62},"Hospital Universitario 12 de Octubre"]